Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 9216217 Oligomer-specific amyloid beta epitope and antibodies

Patent 9216217 was granted and assigned to The University Of British Columbia on December, 2015 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
The University Of British Columbia
The University Of British Columbia
Date Filed
March 3, 2011
Date of Patent
December 22, 2015
Patent Application Number
13582308
Patent Citations Received
‌
US Patent 12071472 Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers
0
‌
US Patent 11779629 Compositions comprising cyclic peptides derived from an A-beta peptide
‌
US Patent 11905318 Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide
0
‌
US Patent 11970522 Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide
0
‌
US Patent 11756650 Systems and methods for predicting misfolded protein epitopes by collective coordinate biasing
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9216217
Patent Primary Examiner
‌
Gregory S Emch

Find more entities like US Patent 9216217 Oligomer-specific amyloid beta epitope and antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.